CytomX Therapeutics (NASDAQ:CTMX) 报告季度每股收益$0.23，超过分析师共识预期的$(0.20)，增长215%。 与去年同期的每股收益$0.01相比增加了2200%。 公司报告季度销售额为$38.09百万，超过分析师共识预期的$19.42百万，增长96.19%。 与去年同期的销售额$26.61百万相比增加了43.17%。

以上内容来自Benzinga Earnings专栏，原文如下：

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $(0.20) by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent. This is a 43.17 percent increase over sales of $26.61 million the same period last year.